(3S,4S)-Tofacitinib,
1092578-47-6,
racemic-Tasocitinib,
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
CHEMBL459769,
C16H20N6O,
3-{(3S,4S)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile,
Tofacitinib Impurity C,
AOB5921,
DTXSID10602594,
3197AH,
BDBM50273930,
HY-40354C,
ZINC13974880,
AKOS016015817,
ACN-027536,
CS-1108,
PB31511,
RL06158,
NCGC00348153-01,
SC-28461,
W-5456,
J-501293,
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyr,
(3S,4S)-Tofacitinib; 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; (3S,4S)-4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-1-piperidinepropanenitrile; 1-Piperidin,
Tofacitinib,
Tasocitinib,
Tofacitinib citrate,
B1031,
1259404-17-5,
477600-75-2,